Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy

INTRODUCTION: Today, a new paradigm has emerged for cancer treatment introducing combination therapies. Doxil, a liposomal doxorubicin serving as a chemotherapeutic agent, is an effective immunogenic killer of cancer cells. Anti-CTLA-4 has been approved for the treatment of some cancers, including m...

Descripción completa

Detalles Bibliográficos
Autores principales: Alimohammadi, Reza, Alibeigi, Razieh, Nikpoor, Amin Reza, Chalbatani, Ghanbar Mahmoodi, Webster, Thomas J, Jaafari, Mahmoud Reza, Jalali, Seyed Amir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394514/
https://www.ncbi.nlm.nih.gov/pubmed/32801691
http://dx.doi.org/10.2147/IJN.S260760

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7394514/
https://www.ncbi.nlm.nih.gov/pubmed/32801691
http://dx.doi.org/10.2147/IJN.S260760

Ejemplares similares